# US 8,277,846 B2 · Complexing agents for compositions containing inclusion complexes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,846 B2
- Document ID: US8277846B2
- Status: Granted
- Kind: B2
- Application number: 13/107,024
- Filed: 2011-05-13
- Published: 2011-10-20
- Granted: 2012-10-02
- Earliest claimed: 2000-12-19
- Assignees: California Institute of Technology; Calando Pharmaceuticals, Inc.
- Inventors: Suzie Hwang Pun; Hector Gonzalez; Mark E. Davis; Nathalie C. Bellocq; Jianjun Cheng
- Web page: https://patentgrep.com/patent/US8277846B2

## CPC

- A61K 48/0041: {the non-active part being polymeric}
- A61K 38/44: Oxidoreductases (1)
- A61K 47/555: {pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells}
- A61K 47/6949: {inclusion complexes, e.g. clathrates, cavitates or fullerenes}
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 31/12: Antivirals
- A61P 35/04: specific for metastasis
- C08B 37/0012: {Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof}
- C08B 37/0015: {Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes}
- C08G 65/33396: {having oxygen in addition to nitrogen}
- C08G 65/48: Polymers modified by chemical after-treatment
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12Y 113/12007: Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C08G 2650/04: End-capping
- C08G 2650/38: containing oxygen in addition to the ether group
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula:

## Claims

### Claim 1

A method of preparing a composition comprising a therapeutic agent and an inclusion complex of a cyclodextrin-containing polymer and a complexing agent of the formula:
wherein
Host/Guest is a guest moiety;
J is —NH—, —C(═O)NH—(CH2)d—, —NH—C(═O)—(CH2)d—, —CH2SS—, —C(═O)O—(CH2)e—O—P(═O)(O—(CH2)e—Y)O—,
a peptide or polypeptide residue, or —NH—(C═O)—CH(R1)—NH—(C═O)—CH(R1)—NH—;
Y is an additional host-guest functionality;
R1 is —(CH2)—CO2H, an ester or salt thereof; or —(CH2)a—CONH2;
PEG is —O(CH2CH2O)z—, where z varies from 2 to 500;
L is —NH—, —NH—(C═O)—(CH2)e—(C═O)—CH2—, —S(═O)2—HC═CH—, —SS—, —C(═O)O—, or a carbohydrate residue;
a is 0 or 1;
b is 0 or 1;
d ranges from 0 to 6;
e ranges from 1 to 6;
m is 1;
n ranges from 1 to 6;
q is 1;
w ranges from 1 to 5;
y is 1; and
x is 1,
said method comprising: combining the cyclodextrin-containing polymer, the complexing agent and the therapeutic agent, thereby forming the composition.

### Claim 2 (depends on 1)

The method of claim 1, wherein the complexing agent has the formula:
wherein J is a peptide or polypeptide residue.

### Claim 3 (depends on 1)

The method of claim 1, wherein the host/guest is selected from adamantyl, naphthyl, cholesterol, and mixtures thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the therapeutic agent is selected from antibiotics, steroids, polynucleotides, small molecule pharmaceuticals, viruses, plasmids, peptides, peptide fragments, chelating agents, natural products, biologically active macromolecules, proteins, enzymes, and mixtures thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the therapeutic agent is a polynucleotide.

### Claim 6 (depends on 1)

The method of claim 1, wherein at least one Functional Group includes a therapeutic agent, a ligand, a nuclear localization signal, an endosomal release peptide, an endosomal release polymer, or a membrane permeabilization agent.

### Claim 7 (depends on 6)

The method of claim 6, wherein at least one Functional Group includes a therapeutic agent.

### Claim 8 (depends on 7)

The method of claim 7, wherein the therapeutic agent is selected from antibiotics, steroids, polynucleotides, small molecule pharmaceuticals, viruses, plasmids, peptides, peptide fragments, chelating agents, natural products, biologically active macromolecules, proteins, enzymes, and mixtures thereof.

### Claim 9 (depends on 6)

The method of claim 6, wherein at least one Functional Group includes a ligand.

### Claim 10 (depends on 9)

The method of claim 9, wherein the ligand is selected from vitamins, proteins, monoclonal antibodies, monosaccharides, peptides, and polysaccharides.

### Claim 11 (depends on 10)

The method of claim 10, wherein the ligand is a protein.

### Claim 12 (depends on 11)

The method of claim 11, wherein the protein is transferrin.

### Claim 13 (depends on 1)

The method of claim 1, wherein a is 1.

### Claim 14 (depends on 1)

The method of claim 1, wherein at least one Functional Group includes at least one polymer portion.

### Claim 15 (depends on 1)

The method of claim 1, wherein the cyclodextrin-containing polymer and the complexing agent are in lyophilized form.

### Claim 16

A method of treating a patient comprising administering to the patient a therapeutically effective amount of a composition comprising a therapeutic agent and an inclusion complex of a cyclodextrin-containing polymer and a complexing agent of the formula:
wherein
Host/Guest is a guest moiety;
J is —NH—, —C(═O)NH—(CH2)d—, —NH—C(═O)—(CH2)d—, —CH2SS—, —C(═O)O—(CH2)e—O—P(═O)(O—(CH2)e—Y)O—,
a peptide or polypeptide residue, or —NH—(C═O)—CH(R1)—NH—(C═O)—CH(R1)—NH—;
Y is an additional host-guest functionality;
R1 is —(CH2)—CO2H, an ester or salt thereof; or —(CH2)a—CONH2;
PEG is —O(CH2CH2O)z—, where z varies from 2 to 500;
L is —NH—, —NH—(C═O)—(CH2)e—(C═O)—CH2—, —S(═O)2—HC═CH—, —SS—, —C(═O)O—, or a carbohydrate residue;
a is 0 or 1;
b is 0 or 1;
d ranges from 0 to 6;
e ranges from 1 to 6;
m is 1;
n ranges from 1 to 6;
q is 1;
w ranges from 1 to 5;
y is 1; and
x is 1.

### Claim 17 (depends on 16)

The method of claim 16, wherein the complexing agent has the formula:
wherein J is a peptide or polypeptide residue.

### Claim 18 (depends on 16)

The method of claim 16, wherein the host/guest is selected from adamantyl, naphthyl, cholesterol, and mixtures thereof.

### Claim 19 (depends on 16)

The method of claim 16, wherein the therapeutic agent is selected from antibiotics, steroids, polynucleotides, small molecule pharmaceuticals, viruses, plasmids, peptides, peptide fragments, chelating agents, natural products, biologically active macromolecules, proteins, enzymes, and mixtures thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the therapeutic agent is a polynucleotide.

### Claim 21 (depends on 16)

The method of claim 16, wherein at least one Functional Group includes a therapeutic agent, a ligand, a nuclear localization signal, an endosomal release peptide, an endosomal release polymer, or a membrane permeabilization agent.

### Claim 22 (depends on 21)

The method of claim 21, wherein at least one Functional Group includes a therapeutic agent.

### Claim 23 (depends on 22)

The method of claim 22, wherein the therapeutic agent is selected from antibiotics, steroids, polynucleotides, small molecule pharmaceuticals, viruses, plasmids, peptides, peptide fragments, chelating agents, natural products, biologically active macromolecules, proteins, enzymes, and mixtures thereof.

### Claim 24 (depends on 21)

The method of claim 21, wherein at least one Functional Group includes a ligand.

### Claim 25 (depends on 24)

The method of claim 24, wherein the ligand is selected from vitamins, proteins, monoclonal antibodies, monosaccharides, peptides, and polysaccharides.

### Claim 26 (depends on 25)

The method of claim 25, wherein the ligand is a protein.

### Claim 27 (depends on 26)

The method of claim 26, wherein the protein is transferrin.

### Claim 28 (depends on 16)

The method of claim 16, wherein a is 1.

### Claim 29 (depends on 16)

The method of claim 16, wherein at least one Functional Group includes at least one polymer portion.

### Claim 30 (depends on 16)

The method of claim 16, wherein the patient is suffering from cystic fibrosis, Gaucher's disease, muscular dystrophy, AIDS, cancer, a cardiovascular condition or a neurological condition.

### Claim 31 (depends on 16)

The method of claim 16, comprising administering the composition via oral administration, inhalation, topical application, parenteral administration, intravenous administration, intranasal administration, intraocular administration, intracranial injection, intraperitoneal injection or pulmonary administration.
